Ketamine Enantiomers - Chirality in Pharmacology

Introduction

Ketamine was developed as an anesthetic in the 1960s and has recently gained attention as a breakthrough treatment for depression. Its two enantiomers have significantly different pharmacological profiles.

Structure Comparison

Both enantiomers share the formula C₁₃H₁₆ClNO. The molecule features a cyclohexanone ring joined to an ortho-chlorophenyl ring, with a methylamino group (-NHCH₃) on the chiral carbon at the ring junction.

Chiral Center

The chiral center is the carbon at the junction of the cyclohexanone ring and the chlorophenyl ring. It bears four different groups: the cyclohexanone ring, the phenyl ring, a methylamino group, and a hydrogen (implicit in the ring system).

Pharmacological Differences

Both enantiomers block NMDA receptors, but S-ketamine binds with 3-4 times greater affinity. This means lower doses of S-ketamine achieve the same anesthetic effect, with a cleaner recovery profile.

Clinical Impact

In 2019, the FDA approved esketamine (Spravato) as a nasal spray for treatment-resistant depression. This was groundbreaking because it targets glutamate pathways rather than serotonin, offering relief within hours rather than weeks.

Key Takeaway

Ketamine shows that even when both enantiomers are active, their potency and side effect profiles can differ substantially. The S-form is preferred for its higher potency and fewer psychomimetic side effects.

Related Topics